Increased Clozapine Plasma Concentrations and Side Effects Induced by Smoking Cessation in 2 CYP1A2 Genotyped Patients
- 1 August 2005
- journal article
- case report
- Published by Ovid Technologies (Wolters Kluwer Health) in Therapeutic Drug Monitoring
- Vol. 27 (4), 539-543
- https://doi.org/10.1097/01.ftd.0000164609.14808.93
Abstract
Clozapine, an atypical antipsychotic, depends mainly on cytochrome P4501A2 (CYP1A2) for its metabolic clearance. CYP1A2 is inducible by smoking, and lower plasma concentrations of clozapine are measured in smokers than in nonsmokers. Case reports have been published on the effects of discontinuing smoking in patients receiving clozapine, which might lead to elevated plasma concentrations and severe side effects. We present 2 cases on the consequences of smoking cessation in patients receiving this drug. In the first patient, smoking cessation resulted, within 2 weeks, in severe sedation and fatigue, with an approximately 3-fold increase of plasma clozapine concentrations. In the second patient, a very high plasma concentration of clozapine (3004 ng/mL) was measured 6 days following a 16-day stay in a general hospital, during which smoking was prohibited. In the latter patient, the replacement of omeprazole, a strong CYP1A2 inducer, by pantoprazole, a weaker CYP1A2 inducer, could have contributed, in addition to smoking cessation, to the observed strong increase of plasma clozapine concentrations. Genotyping of the 2 patients revealed that they were carriers of the AA genotype for the -164C>A polymorphism (CYP1A2*1F) in intron 1 of CYP1A2 gene, which has previously been shown to confer a high inducibility of CYP1A2 by smoking. Thus, at the initiation of clozapine treatment, smoking patients should be informed that, if they decide to stop smoking, they are encouraged to do so but must inform their prescriber beforehand. Also, because of the increased use of no-smoking policies in many hospitals, studies examining the consequences of such policies on the pharmacokinetics/pharmacodynamics of drugs metabolized by CYP1A2, taking into account different CYP1A2 genotypes, are needed.Keywords
This publication has 33 references indexed in Scilit:
- The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirementPharmacogenetics, 2003
- CYP1A2 Activity as Measured by a Caffeine Test Predicts Clozapine and Active Metabolite Norclozapine Steady-State Concentration in Patients With SchizophreniaJournal of Clinical Psychopharmacology, 2001
- Clozapine Serum Concentrations are Lower in Smoking than in Non‐Smoking Schizophrenic PatientsBasic & Clinical Pharmacology & Toxicology, 1999
- Prolonged Sedation and Slowly Decreasing Clozapine Serum Concentrations After an OverdoseJournal of Clinical Psychopharmacology, 1999
- Acute Clozapine Overdose: Plasma Concentration and OutcomePharmacopsychiatry, 1998
- Features and Toxicokinetics of Clozapine in OverdoseTherapeutic Drug Monitoring, 1998
- The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapineBritish Journal of Clinical Pharmacology, 1997
- Will Routine Therapeutic Drug Monitoring Have a Place in Clozapine Therapy?Clinical Pharmacokinetics, 1997
- ClozapineCNS Drugs, 1995
- Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test.British Journal of Clinical Pharmacology, 1994